ARTICLE | Company News

Valeant expects to resolve manufacturing issues

August 16, 2017 11:45 PM UTC

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) said late Wednesday that the CGMP inspection issues identified at its Bausch + Lomb manufacturing facility in Tampa, Fla., will soon be “satisfactorily resolved.”

Earlier this month, Valeant received a second complete response letter from FDA for Vyzulta latanoprostene bunod to reduce intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Valeant said the CRL cited CGMP inspection issues at the Tampa facility and did not identify any safety or efficacy concerns...